Recombinant Human Apoa2 Protein

Total Page：16

File Type：pdf, Size：1020Kb

Leader in Biomolecular Solutions for Life Science Recombinant Human ApoA2 Protein Catalog No.: RP02152 Recombinant Sequence Information Background Species Gene ID Swiss Prot Apolipoprotein A-II(Apo-AII for short), also known as Apolipoprotein A2, is a Human 336 P02652 secreted protein which belongs to the apolipoprotein A2 family. It exists as a disulfide-linked homodimer; and also can form a disulfide- linked heterodimer Tags with APOD. APOA2 is the 2nd most abundant protein of the high density C-6×His lipoprotein particles. This protein may stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism. Defects in Synonyms APOA2 gene might cause apolipoprotein A-II deficiency or hypercholesterolemia. Apo-AII; ApoA-II; apoAII Basic Information Description Product Information Recombinant Human ApoA2 Protein is produced by Mammalian expression system. The target protein is expressed with sequence (Gln24-Gln100) of human Source Purification ApoA2 (Accession #P02652) fused with a 6xHis tag at the C- terminus. Mammalian > 95% by SDS- PAGE. Bio-Activity Endotoxin Storage < 1 EU/μg of the protein by LAL Store the lyophilized protein at -20°C to -80 °C for long term. method. After reconstitution, the protein solution is stable at -20 °C for 3 months, at 2-8 °C for up to 1 week. Formulation Avoid repeated freeze/thaw cycles. Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.Contact us for customized product form or formulation. Reconstitution Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Contact www.abclonal.com Validation Data Recombinant Human ApoA2 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 10-15kDa. Antibody | Protein | ELISA Kits | Enzyme | NGS | Service For research use only. Not for therapeutic or diagnostic purposes. Please visit http://abclonal.com for a complete listing of recommended products..

Copy Link

Recommended publications

The Expression of the Human Apolipoprotein Genes and Their Regulation by Ppars
CORE Metadata, citation and similar papers at core.ac.uk Provided by UEF Electronic Publications The expression of the human apolipoprotein genes and their regulation by PPARs Juuso Uski M.Sc. Thesis Biochemistry Department of Biosciences University of Kuopio June 2008 Abstract The expression of the human apolipoprotein genes and their regulation by PPARs. UNIVERSITY OF KUOPIO, the Faculty of Natural and Environmental Sciences, Curriculum of Biochemistry USKI Juuso Oskari Thesis for Master of Science degree Supervisors Prof. Carsten Carlberg, Ph.D. Merja Heinäniemi, Ph.D. June 2008 Keywords: nuclear receptors; peroxisome proliferator-activated receptor; PPAR response element; apolipoprotein; lipid metabolism; high density lipoprotein; low density lipoprotein. Lipids are any fat-soluble, naturally-occurring molecules and one of their main biological functions is energy storage. Lipoproteins carry hydrophobic lipids in the water and salt-based blood environment for processing and energy supply in liver and other organs. In this study, the genomic area around the apolipoprotein genes was scanned in silico for PPAR response elements (PPREs) using the in vitro data-based computer program. Several new putative REs were found in surroundings of multiple lipoprotein genes. The responsiveness of those apolipoprotein genes to the PPAR ligands GW501516, rosiglitazone and GW7647 in the HepG2, HEK293 and THP-1 cell lines were tested with real-time PCR. The APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, APOL3, APOL5 and APOL6 genes were found to be regulated by PPARs in direct or secondary manners. Those results provide new insights in the understanding of lipid metabolism and so many lifestyle diseases like atherosclerosis, type 2 diabetes, heart disease and stroke.
[Show full text]
Proteomic Analysis of HDL from Inbred Mouse Strains Implicates APOE Associated with HDL in Reduced Cholesterol Effl Ux Capacity Via the ABCA1 Pathway
Supplemental Material can be found at: http://www.jlr.org/content/suppl/2015/12/15/jlr.M063701.DC1 .html ˔ Author’s Choice Proteomic analysis of HDL from inbred mouse strains implicates APOE associated with HDL in reduced cholesterol effl ux capacity via the ABCA1 pathway Nathalie Pamir , 1, * Patrick Hutchins , * Graziella Ronsein , * Tomas Vaisar , * Catherine A. Reardon , † Godfrey S. Getz , † Aldons J. Lusis , § and Jay W. Heinecke * Downloaded from Department of Medicine,* University of Washington , Seattle, WA ; Department of Pathology, † University of Chicago , Chicago, IL ; and Department of Genetics, § University of California at Los Angeles , Los Angeles, CA Abstract Cholesterol effl ux capacity associates strongly Supplementary key words atherosclerosis • cardiovascular risk • mass and negatively with the incidence and prevalence of human spectrometry • high density lipoprotein • apolipoprotein E • ATP bind- CVD. We investigated the relationships of HDL’s size and ing cassette transporter A1 www.jlr.org protein cargo with its cholesterol effl ux capacity using APOB-depleted serum and HDLs isolated from fi ve inbred mouse strains with different susceptibilities to atherosclero- Clinical and epidemiological studies show a robust at Univ of Washington Health Sciences Library SB-55, on February 5, 2016 sis. Like humans, mouse HDL carried >70 proteins linked to inverse association of HDL-cholesterol (HDL-C) levels lipid metabolism, the acute-phase response, proteinase inhi- with CVD risk ( 1 ). In randomized clinical trials, how- bition, and the immune system. HDL’s content of specifi c ever, two drugs, CETP inhibitors and niacin, that elevate proteins strongly correlated with its size and cholesterol ef- fl ux capacity, suggesting that its protein cargo regulates its HDL-C levels by different mechanisms, failed to reduce function.
[Show full text]
Biomolecules
biomolecules Review High-Density Lipoproteins Are Bug Scavengers Olivier Meilhac 1,2,*, Sébastien Tanaka 1,3 and David Couret 1,4 1 Université de la Réunion, Inserm, UMR 1188 Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), F-97490 Sainte-Clotilde, France; [email protected] (S.T.); [email protected] (D.C.) 2 CHU de La Réunion, Centre d’Investigations Clinique 1410, 97410 Saint-Pierre, France 3 AP-HP, Service d’Anesthésie-Réanimation, CHU Bichat-Claude Bernard, 75018 Paris, France 4 CHU de La Réunion, Neurocritical Care Unit, 97410 Saint-Pierre, France * Correspondence: [email protected]; Tel.: +33-262-93-88-11 Received: 7 March 2020; Accepted: 6 April 2020; Published: 12 April 2020 Abstract: Lipoproteins were initially defined according to their composition (lipids and proteins) and classified according to their density (from very low- to high-density lipoproteins—HDLs). Whereas their capacity to transport hydrophobic lipids in a hydrophilic environment (plasma) is not questionable, their primitive function of cholesterol transporter could be challenged. All lipoproteins are reported to bind and potentially neutralize bacterial lipopolysaccharides (LPS); this is particularly true for HDL particles. In addition, HDL levels are drastically decreased under infectious conditions such as sepsis, suggesting a potential role in the clearance of bacterial material and, particularly, LPS. Moreover, “omics” technologies have unveiled significant changes in HDL composition in different inflammatory states, ranging from acute inflammation occurring during septic shock to low-grade inflammation associated with moderate endotoxemia such as periodontal disease or obesity. In this review, we will discuss HDL modifications associated with exposure to pathogens including bacteria, viruses and parasites, with a special focus on sepsis and the potential of HDL therapy in this context.
[Show full text]
Association Between the APOA2 Rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI
biomedicines Article Association between the APOA2 rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI Hatim Boughanem 1 , Borja Bandera-Merchán 2, Pablo Hernández-Alonso 2,3,4 , Noelia Moreno-Morales 5, Francisco José Tinahones 2,3, José Lozano 6 , Sonsoles Morcillo 2,3,* and Manuel Macias-Gonzalez 2,3,* 1 Instituto de Investigación Biomédica de Málaga (IBIMA), Facultad de Ciencias, Universidad de Málaga, 29010 Málaga, Spain; [email protected] 2 Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, 29010 Málaga, Spain; [email protected] (B.B.-M.); [email protected] (P.H.-A.); [email protected] (F.J.T.) 3 Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición, CIBERObn, 28029 Madrid, Spain 4 Human Nutrition Unit, Faculty of Medicine and Health Sciences, Sant Joan Hospital, Institut d’Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain 5 Department of Physiotherapy, School of Health Sciences, University of Malaga-Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain; [email protected] 6 Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Málaga, 29010 Málaga, Spain; [email protected] * Correspondence: [email protected] (S.M.); [email protected] (M.M.-G.); Tel.: +34-951-032-648 (S.M. & M.M.-G.); Fax: +34-27-951-924-651 (S.M. & M.M.-G.) Received: 18 February 2020; Accepted: 25 February 2020; Published: 27 February 2020 Abstract: Background: The interaction between obesity and genetic traits on high density lipoprotein (HDL) levels has been extensively studied.
[Show full text]
Downloaded Separately for CEU (Individuals of Western and Northern European Origin) and YRI (Yoruba in Nigeria) from Hapmap Phase 2
NIH Public Access Author Manuscript Int J Obes (Lond). Author manuscript; available in PMC 2013 September 11. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Int J Obes (Lond). 2013 September ; 37(9): 1211–1220. doi:10.1038/ijo.2012.215. Lipoprotein receptor-related protein 1 variants and dietary fatty acids: meta-analysis of European origin and African American studies CE Smith1, J Ngwa2, T Tanaka3, Q Qi4, MK Wojczynski5, RN Lemaitre6, JS Anderson7, A Manichaikul8, V Mikkilä9, FJA van Rooij10,11, Z Ye12, S Bandinelli13, AC Frazier-Wood14, DK Houston15, F Hu4,16, C Langenberg12, NM McKeown1, D Mozaffarian17,18, KE North19, J Viikari20, MC Zillikens11,21, L Djoussé22, A Hofman10,11, M Kähönen23, EK Kabagambe14, RJF Loos12, GB Saylor7, NG Forouhi12, Y Liu24, KJ Mukamal25, Y-DI Chen26, MY Tsai27, AG Uitterlinden10,11,21, O Raitakari28, CM van Duijn10,11, DK Arnett14, IB Borecki5, LA Cupples2,29, L Ferrucci3, SB Kritchevsky15, T Lehtimäki30, Lu Qi4,16, JI Rotter26, DS Siscovick31, NJ Wareham12, JCM Witteman10,11, JM Ordovás1,32,33, and JA Nettleton34 1Nutrition and Genomics Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA 2Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA 3Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA 4Department of Nutrition, Harvard School of Public Health, Boston, MA, USA 5Department of Genetics, Washington University School of Medicine, St.
[Show full text]
Common Genetic Variations Involved in the Inter-Individual Variability Of
nutrients Review Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence Mohammad M. H. Abdullah 1 , Itzel Vazquez-Vidal 2, David J. Baer 3, James D. House 4 , Peter J. H. Jones 5 and Charles Desmarchelier 6,* 1 Department of Food Science and Nutrition, Kuwait University, Kuwait City 10002, Kuwait; [email protected] 2 Richardson Centre for Functional Foods & Nutraceuticals, University of Manitoba, Winnipeg, MB R3T 6C5, Canada; [email protected] 3 United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA; [email protected] 4 Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; [email protected] 5 Nutritional Fundamentals for Health, Vaudreuil-Dorion, QC J7V 5V5, Canada; [email protected] 6 Aix Marseille University, INRAE, INSERM, C2VN, 13005 Marseille, France * Correspondence: [email protected] Abstract: The number of nutrigenetic studies dedicated to the identification of single nucleotide Citation: Abdullah, M.M.H.; polymorphisms (SNPs) modulating blood lipid profiles in response to dietary interventions has Vazquez-Vidal, I.; Baer, D.J.; House, increased considerably over the last decade. However, the robustness of the evidence-based sci- J.D.; Jones, P.J.H.; Desmarchelier, C. ence supporting the area remains to be evaluated. The objective of this review was to present Common Genetic Variations Involved recent findings concerning the effects of interactions between SNPs in genes involved in cholesterol in the Inter-Individual Variability of metabolism and transport, and dietary intakes or interventions on circulating cholesterol concen- Circulating Cholesterol trations, which are causally involved in cardiovascular diseases and established biomarkers of Concentrations in Response to Diets: cardiovascular health.
[Show full text]
Role of Myeloperoxidase Mediated Oxidative Modification and Apolipoprotein Composition in High Density Lipoprotein Function
ROLE OF MYELOPEROXIDASE MEDIATED OXIDATIVE MODIFICATION AND APOLIPOPROTEIN COMPOSITION IN HIGH DENSITY LIPOPROTEIN FUNCTION by ARUNDHATI UNDURTI Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Thesis Advisor: Dr. Stanley L. Hazen Department of Microbiology and Molecular Biology Cell Biology Program CASE WESTERN RESERVE UNIVERSITY August, 2010 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of _____________________________________________________Arundhati Undurti candidate for the ______________________degreePhD *. Alan Levine (signed)_______________________________________________ (chair of the committee) Stanley Hazen ________________________________________________ Jonathan Smith ________________________________________________ Menachem Shoham ________________________________________________ Mark Chance ________________________________________________ ________________________________________________ (date) _______________________06-30-2010 *We also certify that written approval has been obtained for any proprietary material contained therein. For Amma and Nana TABLE OF CONTENTS List of Figures 3 List of Tables 7 Abbreviations 8 Acknowledgements 11 Abstract 13 Chapter I: Introduction Pathogenesis of Atherosclerosis Endothelial Dysfunction 17 Fatty Streak Formation 17 Advanced Lesion Formation 18 Thrombotic Complications 18 Role of Lipoproteins in Atherosclerosis Lipoprotein Classification and Metabolism 19 High Density Lipoprotein 20 Reverse
[Show full text]
The Genetic Architecture of Fasting Plasma Triglyceride Response to Fenofibrate Treatment
European Journal of Human Genetics (2008) 16, 603–613 & 2008 Nature Publishing Group All rights reserved 1018-4813/08 $30.00 www.nature.com/ejhg ARTICLE The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment Jennifer A Smith*,1, Donna K Arnett2, Reagan J Kelly1, Jose M Ordovas3, Yan V Sun1, Paul N Hopkins4,JamesEHixson5,RobertJStraka6, James M Peacock7 and Sharon LR Kardia1 1Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA; 2Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA; 3Nutrition and Genomics Laboratory, Jean Mayer-United States Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA; 4Cardiovascular Genetics Research, University of Utah, Salt Lake City, UT, USA; 5Human Genetics Center, University of Texas Health Science, Houston, TX, USA; 6Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA; 7Department of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, MN, USA Metabolic response to the triglyceride (TG)-lowering drug, fenofibrate, is shaped by interactions between genetic and environmental factors, yet knowledge regarding the genetic determinants of this response is primarily limited to single-gene effects. Since very low-density lipoprotein (VLDL) is the central carrier of fasting TG, identifying factors that affect both total TG and VLDL–TG response to fenofibrate is critical for predicting individual fenofibrate response. As part of the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study, 688 individuals from 161 families were genotyped for 91 single-nucleotide polymorphisms (SNPs) in 25 genes known to be involved in lipoprotein metabolism.
[Show full text]
Genetic Variants for Personalised Management of Very Low Carbohydrate Ketogenic Diets
Open access Review BMJNPH: first published as 10.1136/bmjnph-2020-000167 on 12 December 2020. Downloaded from Genetic variants for personalised management of very low carbohydrate ketogenic diets Lucia Aronica ,1,2 Jeff Volek,3 Angela Poff,4 Dominic P D'agostino4 To cite: Aronica L, Volek J, ABSTRACT into the basic science of ketones and their Poff A, et al. Genetic variants The ketogenic diet (KD) is a low- carbohydrate, high- applications across broad disciplines. Ketones for personalised management of fat, adequate- protein diet proven to be effective for demonstrate pleiotropic actions affecting very low carbohydrate ketogenic the reversal of obesity, metabolic syndrome and type diets. BMJ Nutrition, Prevention gene expression and pathways regulating 2 diabetes, and holding therapeutic potential for the & Health 2020;0. doi:10.1136/ inflammation, oxidative stress, immune func- prevention and treatment of other chronic diseases. bmjnph-2020-000167 tion, membrane health, cell signalling and Genetic and dynamic markers of KD response may help to 7 ► Additional material is identify individuals most likely to benefit from KD and point antioxidant status that manifest in reversal of published online only. To view, to individuals at higher risk for adverse health outcomes. metabolic disease and extended healthspan. please visit the journal online Here, we provide a clinician-friendly review of state-of- the- The most remarkable therapeutic evidence (http:// dx. doi. org/ 10. 1136/ art research on biomarkers of KD response for a variety of KDs is the rapid and sustained reversal of bmjnph- 2020- 000167). of outcomes including weight loss, body composition and obesity, metabolic syndrome (MetS) and type 1Nutrition Science, Metagenics cognitive performance drawing data from both intervention 2 diabetes in a plethora of recent published Inc, Gig Harbor, Washington, USA trials and case reports of rare inborn errors of metabolism.
[Show full text]
Apoa2 Correlates to Gestational Age with Decreased Apolipoproteins A2, C1, C3 and E in Gestational Diabetes
Metabolism BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2020-001925 on 5 March 2021. Downloaded from Open access Original research apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes Manjunath Ramanjaneya ,1 Alexandra E Butler ,2 Mohammed Bashir,3 Ilham Bettahi,1 Abu Saleh Md Moin,2 Lina Ahmed,4 Mohamed A Elrayess ,5 Steven C Hunt ,4 Stephen L Atkin,6 Abdul Badi Abou- Samra1 To cite: Ramanjaneya M, ABSTRACT Butler AE, Bashir M, Introduction Pregnant women with gestational diabetes Significance of this study et al. apoA2 correlates to mellitus (GDM) are at risk of adverse outcomes, including gestational age with decreased gestational hypertension, pre- eclampsia, and preterm What is already known about this subject? apolipoproteins A2, C1, C3 delivery. This study was undertaken to determine if ► Pregnant women with gestational diabetes are at and E in gestational diabetes. risk of adverse outcomes, including hypertension, BMJ Open Diab Res Care apolipoprotein (apo) levels differed between pregnant women with and without GDM and if they were associated pre-ec lampsia, and pre-term delivery, and apolipo- 2021;9:e001925. doi:10.1136/ proteins (apos) may be mechanistically involved in bmjdrc-2020-001925 with adverse pregnancy outcome. Research design and methods Pregnant women (46 the pathophysiology of these adverse outcomes. women with GDM and 26 women without diabetes (ND)) in What are the new findings? ► Supplemental material is their second trimester were enrolled in the study. Plasma ► apoA2, apoC1, apoC3 and apoE levels were reduced published online only. To view, apos were measured and correlated to demographic, please visit the journal online in women with gestational diabetes, while apoA2 biochemical, and pregnancy outcome data.
[Show full text]
Apolipoprotein A-II Induces Acute-Phase Response Associated
www.nature.com/scientificreports OPEN Apolipoprotein A-II induces acute- phase response associated AA amyloidosis in mice through Received: 2 October 2017 Accepted: 16 March 2018 conformational changes of plasma Published: xx xx xxxx lipoprotein structure Mu Yang 1,2, Yingye Liu1,3, Jian Dai1, Lin Li1, Xin Ding1, Zhe Xu1, Masayuki Mori1,4, Hiroki Miyahara1, Jinko Sawashita1,5 & Keiichi Higuchi1,5 During acute-phase response (APR), there is a dramatic increase in serum amyloid A (SAA) in plasma high density lipoproteins (HDL). Elevated SAA leads to reactive AA amyloidosis in animals and humans. Herein, we employed apolipoprotein A-II (ApoA-II) defcient (Apoa2−/−) and transgenic (Apoa2Tg) mice to investigate the potential roles of ApoA-II in lipoprotein particle formation and progression of AA amyloidosis during APR. AA amyloid deposition was suppressed in Apoa2−/− mice compared with wild type (WT) mice. During APR, Apoa2−/− mice exhibited signifcant suppression of serum SAA levels and hepatic Saa1 and Saa2 mRNA levels. Pathological investigation showed Apoa2−/− mice had less tissue damage and less infammatory cell infltration during APR. Total lipoproteins were markedly decreased in Apoa2−/− mice, while the ratio of HDL to low density lipoprotein (LDL) was also decreased. Both WT and Apoa2−/− mice showed increases in LDL and very large HDL during APR. SAA was distributed more widely in lipoprotein particles ranging from chylomicrons to very small HDL in Apoa2−/− mice. Our observations uncovered the critical roles of ApoA-II in infammation, serum lipoprotein stability and AA amyloidosis morbidity, and prompt consideration of therapies for AA and other amyloidoses, whose precursor proteins are associated with circulating HDL particles.
[Show full text]
D25V Apolipoprotein C-III Variant Causes Dominant Hereditary Systemic Amyloidosis and Confers Cardiovascular Protective Lipoprotein Profile
ARTICLE Received 1 Jun 2015 | Accepted 2 Dec 2015 | Published 21 Jan 2016 DOI: 10.1038/ncomms10353 OPEN D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile Sophie Valleix1,2,3,4,w, Guglielmo Verona5,6, Noe´mie Jourde-Chiche7, Brigitte Ne´delec2,3,4, P. Patrizia Mangione5,6, Frank Bridoux8, Alain Mange´9,10,11,12, Ahmet Dogan13,14, Jean-Michel Goujon15, Marie Lhomme16, Carolane Dauteuille17, Miche`le Chabert4,17,18, Riccardo Porcari5, Christopher A. Waudby19, Annalisa Relini20, Philippa J. Talmud21, Oleg Kovrov22, Gunilla Olivecrona22, Monica Stoppini6, John Christodoulou19, Philip N. Hawkins5, Gilles Grateau23, Marc Delpech1, Anatol Kontush17, Julian D. Gillmore5, Athina D. Kalopissis4 & Vittorio Bellotti5,6 Apolipoprotein C-III deficiency provides cardiovascular protection, but apolipoprotein C-III is not known to be associated with human amyloidosis. Here we report a form of amyloidosis char- acterized by renal insufficiency caused by a new apolipoprotein C-III variant, D25V. Despite their uremic state, the D25V-carriers exhibit low triglyceride (TG) and apolipoprotein C-III levels, and low very-low-density lipoprotein (VLDL)/high high-density lipoprotein (HDL) profile. Amyloid fibrils comprise the D25V-variant only, showing that wild-type apolipoprotein C-III does not contribute to amyloid deposition in vivo. The mutation profoundly impacts helical structure stability of D25V-variant, which is remarkably fibrillogenic under physiological conditions in vitro producing typical amyloid fibrils in its lipid-free form. D25V apolipoprotein C-III is a new human amyloido- genic protein and the first conferring cardioprotection even in the unfavourable context of renal failure, extending the evidence for an important cardiovascular protective role of apolipoprotein C-III deficiency.
[Show full text]